Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17781177 | 0.87 | KDM4E (0.47) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL22105282 | 0.86 | KDM4E (0.46) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL22578630 | 0.86 | KDM4E (0.46) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL22105272 | 0.85 | TGFBR1 (0.48) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL22820298 | 0.85 | KDM4E (0.45) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL28443740 | 0.81 | KDM4E (0.36) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL29220714 | 0.80 | ALDH1A1 (0.54) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL22857888 | 0.80 | NPC1 (0.42) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL17781294 | 0.79 | KDM4E (0.49) | KDM4ENPC1RAB9AALDH1A1HPGD | |
| SCHEMBL22820256 | 0.78 | KDM4E (0.45) | KDM4ENPC1RAB9AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113773335-B | Compound serving as protein kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-111511746-B | Macrocyclic compounds for the treatment of diseases | 特普医药公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20230219978-A1 | COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219978-A1 | COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219978-A1 | COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD (CN) | 2023-07-13 | — | — | US | disclosed |
| EP-4163283-A1 | COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF | Scinnohub Pharmaceutical Co., Ltd (CN) | 2023-04-12 | — | — | EP | disclosed |
| EP-4163283-A1 | COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF | Scinnohub Pharmaceutical Co., Ltd (CN) | 2023-04-12 | — | — | EP | disclosed |
| EP-4151641-A1 | MACROCYCLIC COMPOUNDS FOR TREATING CANCER | Turning Point Therapeutics, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| CN-113754682-B | Compound having macrocyclic structure and use thereof | 赛诺哈勃药业（成都）有限公司 | 2023-01-06 | — | — | CN | disclosed |
| US-20220411439-A1 | POLYMORPHS OF A MACROCYCLIC KINASE INHIBITOR | Turning Point Therapeutics, Inc. | 2022-12-29 | — | — | US | disclosed |
| CN-112110938-B | Compound as protein kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2021-11-09 | — | — | CN | disclosed |
| US-20210087206-A1 | MACROCYCLIC KINASE INHIBITORS AND THEIR USE | TURNING POINT THERAPEUTICS INC (US) | 2021-03-25 | — | — | US | disclosed |
| WO-2020257169-A1 | POLYMORPHS OF A MACROCYCLIC KINASE INHIBITOR | Turning Point Therapeutics, Inc. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020257169-A1 | POLYMORPHS OF A MACROCYCLIC KINASE INHIBITOR | Turning Point Therapeutics, Inc. (US) | 2020-12-24 | — | — | WO | disclosed |
| CN-112110938-A | Compound as protein kinase inhibitor and preparation method and application thereof | 成都海博为药业有限公司 | 2020-12-22 | — | — | CN | disclosed |
| US-20200392160-A1 | MACROCYCLIC COMPOUNDS FOR TREATING DISEASE | TP THERAPEUTICS, INC. | 2020-12-17 | — | — | US | disclosed |
| EP-3728271-A1 | MACROCYCLIC COMPOUNDS FOR TREATING DISEASE | Turning Point Therapeutics, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-3728270-A1 | MACROCYCLIC KINASE INHIBITORS AND THEIR USE | Turning Point Therapeutics, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-10745416-B2 | Macrocyclic compounds for treating disease | Turning Point Therapeutics, Inc. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200190110-A1 | MACROCYCLIC COMPOUNDS FOR TREATING DISEASE | Turning Point Therapeutics, Inc. (US) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411439-A1 | POLYMORPHS OF A MACROCYCLIC KINASE INHIBITOR | MAP3K20, MAP3K19, MAP3K15 | KDM4E 1475/4885NPC1 2516/4885RAB9A 1302/4885 |
| US-20200392160-A1 | MACROCYCLIC COMPOUNDS FOR TREATING DISEASE | VHL, DLD, PC | KDM4E 3114/4885NPC1 8/4885RAB9A 1598/4885 |
| US-20200190110-A1 | MACROCYCLIC COMPOUNDS FOR TREATING DISEASE | VHL, DLD, PC | KDM4E 3114/4885NPC1 8/4885RAB9A 1598/4885 |
| US-10745416-B2 | Macrocyclic compounds for treating disease | VHL, DLD, PC | KDM4E 3114/4885NPC1 8/4885RAB9A 1598/4885 |
| US-20210087206-A1 | MACROCYCLIC KINASE INHIBITORS AND THEIR USE | MAP3K20, LCK, MAP3K1 | KDM4E 1234/4885NPC1 3113/4885RAB9A 1751/4885 |
| US-20230219978-A1 | COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF | BTK, SRC, YES1 | KDM4E 1626/4885NPC1 3462/4885RAB9A 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.